TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03448198

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total knee replacement
Description: Primary knee gonarthrosis treated with navigated total knee replacement and computer-assisted patellar replacement.
Study: NCT00519350

Intervention type: PROCEDURE
Intervention: Blood collection
Description: In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation

Intervention type: PROCEDURE
Intervention: Blood collection
Description: In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation

Intervention type: PROCEDURE
Intervention: Blood collection
Description: In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
Study: NCT03789877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participate in home-based walking program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Participate in home-based walking program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Undergo rTMS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Intervention
Description: Undergo sham rTMS
Study: NCT02525068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Until confirmed disease progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD5363
Description: Until confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Until confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Until confirmed disease progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enzalutamide
Description: Until confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Until confirmed disease progression.
Study: NCT04642222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APOLO-Teens web-based intervention
Description: The APOLO-Teens web-based intervention is a 6-month cognitive-behavioral lifestyle program developed to optimize treatment as usual for pediatric obesity in public portuguese hospitals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual for Pediatric Obesity
Description: Treatment as Usual for pediatric obesity in portuguese public hospitals.
Study: NCT01366716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash CM
Description: Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher CM
Description: Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
Study: NCT01217346

Intervention type: OTHER
Intervention: no intervention is involved in this study
Description: no intervention is involved in this study
Study: NCT04222049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibro Tactile Gadget
Description: The concept is to apply vibro tactile gadget to different nerve points which when applied transmit waves to the focused parts of brain which will result in blood flow and activation of dead cells. As a result some disabled part of the body because of those dead cells can show improvement.
Study: NCT02673749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-G28
Description: Study drug taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-G28
Description: Study drug taken orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally
Study: NCT03122106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen DNA vaccine
Description: -Personalized polyepitope inserts integrating the prioritized neoantigens and mesothelin epitopes will be designed and then synthesized and cloned into the pING parent vector

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDS-IM Electrode Array System
Description: -Ichor Medical Systems

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draws
Description: -Enrollment, mid adjuvant chemotherapy, end of chemotherapy, week 1, week 5, week 9, week 13, week 17, week 21, week 25, and week 77
Study: NCT02707497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will not use any platelet-increased drugs.
Study: NCT03039075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin SR Tablet
Description: Metformin SR Tablet made in Conquer pharmaceutical co., LTD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin SR Tablet
Description: Metformin SR Tablet made in Conquer pharmaceutical co., LTD
Study: NCT03100877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pheresis
Description: Undergo apheresis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Undergo TMI
Study: NCT01457794

Intervention type: OTHER
Group type: OTHER
Intervention: School meals based on the principles of the New Nordic Diet
Description: The study participants are provided with three daily school meals for 3 month

Intervention type: OTHER
Group type: OTHER
Intervention: School meals based on the principles of the New Nordic Diet
Description: The study participants are provided with three daily school meals for 3 month
Study: NCT01867775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine 15 mg, at night, once a day for 14 days
Study: NCT04627636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial trigger points pressure (MTrP) release
Description: Myofascial trigger points pressure (MTrP) release technique, the initial step was to recognize and find the trigger points (TP) , and The second step after TP palpation was the MTrP release technique, as follow, by one or both hands, the thumbs or four fingers of the therapist applied a maintained pressure, pushing internal toward the middle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shockwave therapy application
Description: The JEST-2000 (JOEUN Medical, Dae-Jeon, South Korea) was used for the ESWT. The application of pressure pulses of ESWT was centered around the flexor muscles with hypertonia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: Passive ROM exercises performed by the therapist and Bobath Neurodevelopmental Approach (prolonged stretch): The Intervention methods for Bobath involved the activation of key points of control for the reduction of tone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: Passive ROM exercises performed by the therapist and Bobath Neurodevelopmental Approach (prolonged stretch): The Intervention methods for Bobath involved the activation of key points of control for the reduction of tone
Study: NCT02025608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02346864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three-stair-position
Description: Infants in the TSP group received three-stair-prone position. Implementation steps were as following: 1) produced pad of three-stair-prone position the total height of which should be the same height as the head elevated 15 °. 2) Placed the infants on the pad with head on the highest ladder, chest on the second step and leg on the third step, bending the knees to the chest

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Head elevated tilt position group
Description: Infants in the HETP group were allowed head up 15 ° prone position using a protractor with head to one side, arms against the sides of the body naturally bending, knees bent to the chest.
Study: NCT02457091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: strength training consists of 1-3 sets , 10-15 repetitions of 10 exercises targeting lower body, upper body and core muscle groups
Study: NCT00591539

Intervention type: PROCEDURE
Intervention: Carotid Ultrasound
Description: Bilateral carotid ultrasound measurements: A test that uses sound waves to look at the blood vessels in the neck.
Study: NCT00703209

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Decompression
Description: Nerve decompression on a randomized leg, with similar skin incisions on the opposite leg so that the patient is blinded to which leg received the decompression.
Study: NCT02668549

Intervention type: OTHER
Intervention: DB review for Doctor/Pharmacy Shopping Behavior
Description: Database review to evaluate of doctor/pharmacy shopping behaviors

Intervention type: OTHER
Intervention: DB review for Doctor/Pharmacy Shopping Behavior
Description: Database review to evaluate of doctor/pharmacy shopping behaviors
Study: NCT01973244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.~Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
Study: NCT02457091

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
Study: NCT00636727

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrocentesis
Description: Irrigate the TMJ with lactated ringers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopy
Description: The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroplasty
Description: The disc will be surgically repositioned with open surgery
Study: NCT06292052

Intervention type: DRUG
Intervention: Immunotherapy
Description: Received neoadjuvant chemotherapy plus immunotherapy
Study: NCT01710644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burlulipase
Description: Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Caramel in sterile water)
Description: Placebo will be taken with meals and snacks for 5 to 7 days
Study: NCT04510090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP547
Description: EP547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP547
Description: EP547

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01566877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVI-7288
Description: Cohort 1: AVI-7288 at 1 mg/kg IV; Cohort 2: AVI-7288 at 4 mg/kg IV;Cohort 3: AVI-7288 at 8 mg/kg IV; Cohort 4: AVI-7288 at 12 mg/kg IV~The amount of AVI-7288 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline Solution (NSS)
Study: NCT02748772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two Anti-angiogenesis Drugs（Endostar and Thalidomide）
Description: Endostar:30 mg/d, CIV (continous intravenous pumping) on day 7 of each 21 day cycle，5 days before the chemotherapy is the first day; Thalidomide:100-200mg/d,PO (peros) on day 14 of each 21 day cycle Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pure chemotherapy（Xelox）
Description: CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pure chemotherapy（Xelox）
Description: CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
Study: NCT00067080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670, deferoxamine
Study: NCT02066571

Intervention type: DRUG
Group type: OTHER
Intervention: Droxidopa
Description: Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.

Intervention type: DRUG
Group type: OTHER
Intervention: Droxidopa
Description: Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.

Intervention type: DRUG
Group type: OTHER
Intervention: sugar pill
Description: Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.

Intervention type: DRUG
Group type: OTHER
Intervention: sugar pill
Description: Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
Study: NCT03647592

Intervention type: DRUG
Intervention: Erlotinib/Gefitinib combined with Bevacizumab
Description: Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months
Study: NCT00122603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir
Description: ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir
Description: ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)
Study: NCT03251417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150mg/m2, repeated very 2 weeks for 3 to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500 mg oral take, daily
Study: NCT01860196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meditoxin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Study: NCT04546841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multipeptide cocktail
Description: Three groups of participant will be administered the multipeptide cocktail~1. Part I: Age 18-55 at the time of screening~2. Part II: Age 56-74 years at the time of screening~3. Part III: Age ≥ 75 years at the time of screening
Study: NCT00460967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rheopheresis
Description: 8 rheopheresis treatments over 10 wks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Rheopheresis
Description: Sham treatment
Study: NCT00687700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 matching placebo
Description: GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol matching placebo
Description: Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.
Study: NCT04315402

Intervention type: OTHER
Intervention: prospective, descriptive study via survey
Description: * Survey administered at check out.~* Patient's rate of follow-up data gathered via chart review.

Intervention type: OTHER
Intervention: prospective, descriptive study via survey
Description: * Survey administered at check out.~* Patient's rate of follow-up data gathered via chart review.
Study: NCT02164916

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: Given PO
Study: NCT03413735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Tea Extract
Description: Confections containing green tea extract that will be ingested daily for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Confections containing no green tea extract that will be ingested daily for 4 weeks
Study: NCT04501900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Study subjects diagnosed as stable, unstable ischemic coronary disease or myocardial infarction planning to undergo percutaneous coronary intervention (PCI) and no contradiction to prolonged DAPT are eligible for this trial. All subjects will provide written informed consent to participate. Subjects will be enrolled into the study before or within 24 hours after the index procedure. Subjects will be randomized to either discontinue P2Y12 inhibitor (clopidogrel or ticagrelor) (12 months total) or receive P2Y12 inhibitor for an additional 24 months (36 months total). Aspirin will be maintained in the entire study and can be replaced by cilostazol or indobufen if subjects are intolerant. Dosage of antiplatelet drugs will be according to local standard of practice. Subjects will be treated with XINSORB BRS only.
Study: NCT00964782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will be randomized to receive Sildenafil first and then crossed over to receive the opposite intervention, placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will receive a look-alike placebo. Enrolled patients will be randomized to receive Placebo first and then crossed over to receive the opposite intervention, Sildenafil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil 2
Description: oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will receive Sildenafil, the crossed over intervention from their initial intervention (Placebo).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Patient will receive a look-alike placebo. Enrolled patients will receive Placebo, the crossed over intervention from their initial intervention (Sildenafil).
Study: NCT01922583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
Study: NCT01010763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Degenerated hip is replaced with implantable devices, which include femoral stem, acetabular cup, femoral head and acetabular liner(control group only).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Degenerated hip is replaced with implantable devices, which include femoral stem, acetabular cup, femoral head and acetabular liner(control group only).
Study: NCT03789721

Intervention type: OTHER
Intervention: Medical Record Abstraction
Description: Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.

Intervention type: OTHER
Intervention: Biospecimen Sample Collection
Description: Collect research samples, when feasible for those diagnosed with ALD.